Drugs / JNJ-89853413
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06618001 | Jan 2025 → Jul 2027 expected | acute myeloid leukemia, myelodysplastic syndrome | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-89853413 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06618001 ↗ |